Loading...
•
Jun 30
West Pharma Q2 2025 Earnings Report
West Pharma reported strong Q2 2025 results with solid HVP growth and raised full-year guidance.
Key Takeaways
West Pharmaceutical Services delivered $766.5 million in net sales for Q2 2025, driven by strong growth in proprietary products, especially high-value components and delivery devices. Net income rose to $131.8 million, and adjusted EPS increased to $1.84. The company raised its full-year 2025 guidance on both revenue and adjusted EPS.
Net sales reached $766.5 million, up 9.2% year-over-year.
Organic net sales grew 6.8%, driven by strong high-value product components.
Net income increased to $131.8 million, with adjusted diluted EPS at $1.84.
Proprietary Products revenue rose 10.7%, while Contract-Manufactured Products grew 3.0%.
West Pharma
West Pharma
West Pharma Revenue by Segment
Revenue by Segment
Proprietary Products Revenue
CapyFin.comContract-Manufactured Products Revenue
CapyFin.com Forward Guidance
West Pharma raised full-year 2025 guidance, expecting higher revenue and EPS supported by strong HVP demand and favorable foreign exchange impacts.
Positive Outlook
- Raised full-year 2025 revenue guidance to $3.04–$3.06 billion.
- Adjusted EPS guidance increased to $6.65–$6.85.
- Strong momentum in HVP components and delivery devices.
- Favorable foreign exchange tailwind of approximately $59 million.
- Continued strong demand in biologics, pharma, and generics markets.
Challenges Ahead
- Contract-Manufactured Products grew only 0.5% organically.
- Higher tariffs expected to negatively impact EPS by $15–$20 million.
- Asia Pacific growth not highlighted, indicating slower demand regionally.
- Standard products showed minimal growth at 0.4%.
- Operating expenses increased, partly offsetting margin expansion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income